Forced expiratory volume in one second (FEV ) is an important Background: cystic fibrosis (CF) prognostic marker and an established endpoint for CF clinical trials. FEV is also used in observation studies, e.g. to compare different centre's outcomes. We wished to evaluate whether different methods of processing FEV data can impact on a centre's outcome. This is a single-centre retrospective analysis of routinely collected Methods: data from 2013-2016 which included 208 adults with CF. Year-to-year %FEV change was calculated by subtracting best %FEV at Year 1 from Year 2 (i.e. negative values indicate %FEV decline), and compared using Friedman test. Three methods were used to process %FEV data. First, %FEV calculated with Knudson equation was extracted directly from spirometer machines. Second, FEV volume were extracted then converted to %FEV using clean height data and Knudson equation. Third, FEV volume were extracted then converted to %FEV using clean height data and GLI equation. In addition, %FEV decline calculated using GLI equation was adjusted for baseline %FEV to understand the impact of case-mix adjustment.
was compared using a standard related group non-parametric statistical test. Observational studies with %FEV decline as an outcome measure should carefully consider and clearly specify the data processing methods used. 
Keywords

Introduction
Cystic fibrosis (CF) is a multi-system genetic condition but the two main affected organs are lungs (resulting in recurrent infections and respiratory failure) and gastrointestinal tract (resulting in fat malabsorption and poor growth) 1 . Median survival has improved to 45 years, in part because of improvement in care quality 2 . An important quality improvement initiative is benchmarking, which involves identifying high-performing centres and the practices associated with outstanding performance [3] [4] [5] . Since forced expiratory volume in one second (FEV 1 ) is an important CF prognostic marker [6] [7] [8] [9] , it is often used as an outcome measure for benchmarking [3] [4] [5] 10 .
Different statistical methods of analysing FEV 1 data can yield different results
11
, but there is scant attention paid to the methods of processing FEV 1 data. We previously reported a statistically significant reduction in %FEV 1 decline for our CF centre from [2013] [2014] [2015] [2016] 12 . We now set out to understand the impact of using different FEV 1 data processing methods on our CF centre's outcome.
Methods
This is a single-centre retrospective analysis of routinely collected clinical data from 2013-2016. Regulatory approval for the analysis was obtained from NHS Health Research Authority (IRAS number 210313). All adults with CF diagnosed according to the UK CF Trust criteria aged ≥16 years were included, except those with lung transplantation or on ivacaftor. These treatments have transformative effects on %FEV 1 [13] [14] [15] , thus may affect the interpretation of %FEV 1 decline.
Demographic data (age, gender, genotype, pancreatic status, CF related diabetes, Pseudomonas aeruginosa status), body mass index (BMI) and FEV 1 data were collected by two investigators (HZH and RC / HZH and MEG) independently reviewing paper notes and electronic records. Where data from the two investigators differ, the original data from paper notes or electronic records were reviewed to by both investigators to ensure the accuracy of abstracted data. This process ensures the accuracy of abstracted data and helps avoid potential bias from inaccurate or inconsistent data collection 16 . FEV 1 data were processed with three different methods prior to analysis. First, %FEV 1 readings (calculated with Knudson equation 17 and available in whole numbers) were directly extracted from spirometer machines. Second, FEV 1 volumes (in litres, to two decimal places) were extracted and clean height data were used to calculate %FEV 1 (as whole numbers) with Knudson equation 17 . Third, FEV 1 volumes (in litres, to two decimal places) were extracted and clean height data were used to calculate %FEV 1 with GLI equation 18 using an Excel Macro (Microsoft Excel 2013).
Best %FEV 1 , i.e. the highest %FEV 1 reading in a calendar year for each study subject was used for analysis since it is most reflective of the true baseline %FEV 1
19
. Year-to-year %FEV 1 change was calculated by subtracting best %FEV 1 at Year 1 from Year 2 (i.e. negative values indicate %FEV 1 decline and positive values indicate increase in %FEV 1 ). In addition to calculating year-toyear %FEV 1 change using three different FEV 1 data processing methods, %FEV 1 change calculated with GLI equation was also adjusted for baseline %FEV 1 using reference values from Epidemiologic Study of CF (ESCF) 20 . The ESCF study found median %FEV 1 change of -3%/year, -2%/year and -0.5%/year for baseline %FEV1 ≥100%, 40-99.9% and <40% respectively 20 . Adjusted %FEV 1 change was calculated by subtracting median ESCF %FEV 1 change from actual %FEV 1 change. Thus, an adjusted %FEV 1 change >0 meant the subject's %FEV1 decline was less than expected (indicating better health outcome) whilst an adjusted %FEV 1 change <0 meant the subject's %FEV 1 decline was more than expected (indicating worse health outcome). %FEV 1 change from 2013-2014 to 2015-2016 calculated using different FEV 1 data processing methods were compared using Friedman test. Analyses were performed using SPSS v24 (IBM Corp) and p-value <0.05 was considered statistically significant.
Results
This analysis included 208 adults, with 147 adults providing data for all four years. Overall, the cohort was ageing but baseline %FEV 1 increased from 2014 onwards (see Table 1 ).
The %FEV 1 increase was in part due to younger adults with higher %FEV 1 transitioning from paediatric care because %FEV 1 tended to decline from year to year (see Table 2 ). However, different %FEV 1 decline results were obtained with different FEV 1 data processing methods. There was statistically significant reduction in the rate of %FEV 1 decline using %FEV 1 readings as recorded in spirometer machines (p=0.016). Cleaning of height data and standardisation of %FEV 1 calculation with Knudson equation 17 did not alter the magnitude of %FEV 1 decline, but the p-value was no longer statistically significant (p=0.062). The use of GLI equation altered the magnitude of %FEV 1 decline although the trend of reduction in %FEV 1 decline persisted (p=0.135). Adjustment for baseline %FEV 1 further increased the p-value (p=0.210). 
Discussion
We demonstrated that different centre-level %FEV 1 decline results were obtained using different FEV 1 data processing methods. In particular, year-on-year %FEV 1 decline was smaller in magnitude when %FEV 1 was calculated using GLI equation 18 instead of Knudson equation 17 . This is in part due to the demographic of our centre which has a relatively young adult population. A previous study found a near-linear %FEV 1 decline from childhood to adulthood with GLI equation, whereas there was accelerated %FEV 1 decline during adolescence and young adulthood when %FEV 1 was calculated with Knudson equation 21 . One advantage of using the GLI equation, which is seamless across all ages, is that it improves the interpretation of %FEV 1 decline 21, 22 . Another advantage is that %FEV 1 decline can be adjusted for baseline %FEV 1 using ESCF reference values (since the ESCF values for %FEV 1 decline were calculated using the GLI equation ESCF -Epidemiologic Study of cystic fibrosis † The vast majority of the %FEV 1 data were from spirometer machines at the Sheffield Adult cystic fibrosis (CF) centre, which were calculated with Knudson equation 17 in whole numbers. Some %FEV 1 data were from spirometer machines at the Pulmonary Function Unit which operationalised the Knudson equation differently; by calculating age to one decimal place to determine the predicted FEV 1 . These spirometer machines also provided %FEV 1 to two decimal places, but this was rounded to whole numbers for the purpose of analysis. These results were presented at the 2017 North American CF Conference and were published as an abstract in Pediatric Pulmonology 12 . ‡ FEV 1 volumes were available in litres to two decimal places from spirometer machines. Height data were also extracted to allow the calculation of predicted FEV 1 . This led us to uncover the inconsistency recording of height, which affected 30-40% of the study subjects and would have introduced erroneous variability to the %FEV 1 because all equations for predicted %FEV 1 are dependent on height. Height data were cleaned to weed out error. Where there was uncertainty regarding the height, the higher value was used to obtain a conservative estimate of %FEV 1 . To replicate calculation process of the spirometer machines at the Sheffield Adult CF centre, age was rounded down to a whole number and predicted FEV 1 in volume were calculated to two decimal places using Knudson equation 17 . This was used to derive the %FEV 1 , which was then rounded to whole numbers for the purpose of analysis.
ϕ FEV 1 and height data were extracted as above. %FEV 1 was calculated using the GLI equation 18 using an Excel Macro available at the European Respiratory Society website. § %FEV 1 calculated using the GLI equation 18 as described above, then adjusted for baseline %FEV 1 as described in the 'Methods' section. An adjusted %FEV 1 change of >0 meant the subject's %FEV 1 decline was less than expected for his / her baseline %FEV 1 , indicating better health outcomes.
The limitation for all single-centre analysis is the potential lack of generalisability. Another limitation of our analysis is that the ESCF reference values used to adjust %FEV 1 decline were derived using a cohort from around 15 years ago 20 , and may not represent the current population. Our results nonetheless highlighted that %FEV 1 decline can be extremely sensitive to the FEV 1 data processing methods. This is one of the challenges of using %FEV 1 decline to infer quality of care. Another challenge is that %FEV 1 lacks sensitivity as an outcome measure. A recent sample size estimation using the UK CF registry data suggests that 273 adults per centre are needed to detect a 5% FEV 1 difference at the 95% significance level 25 . The sensitivity of measures used to detect variations in care quality is particularly pertinent to CF because a relatively small population is spread across many centres. Indeed, only 6/28 (21.4%) of all UK adult CF centres have ≥273 adults. That means process measures, e.g. medication adherence, is important to detect variations in quality of CF care. Mant & Hicks previous demonstrated that measuring processes of care proven in randomised controlled trials to reduce death allows detection of meaningful differences in care quality for myocardial infarction with just 75 cases, whereas 8179 cases would be needed if mortality was used as the quality indicator 26 .
Given the limitations of FEV 1 as an outcome measure in CF, results of centre comparisons based on FEV 1 data should be carefully interpreted. Observational studies with %FEV 1 decline as an outcome measure should carefully consider and clearly specify the data processing methods used.
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The paper supports the standardization of FEV1 collection and reference equations which is currently in development by CF International Registries. It also highlights that different approaches to data collection can impact the interpretation of statistical analyses.
Comments:
Differences in FEV1 percent predicted using different equations is well known (Rosenfeld et al and more recently in the cited UK/US comparison study). For this reason, the GLI have been recently accepted as the standard for most CF registries.
Although year to year subtraction is a method of looking at longitudinal changes, regression methodology is preferable to analyse these changes, especially, as in this case, where you have 3 time points. This also allows to adjust for baseline factors such as lung disease severity.
The method of adjustment for baseline Iung function is a bit crude. The medians subtracted are from a US population over 10 years ago and are likely to overestimate lung function decline in this population. In the Morgan et al, J Pediatr 2016 paper cited, the benefits of using this type of adjustment was shown using regression.
Did their statistical approach factor in that these were repeated measures in the same patients?
Bland & Altman plots comparing different reference equations could be considered.
The results suggest that height inaccuracy is impacting the results. As this is a single centre study, it is difficult to determine is this is a more universal problem. We thank Prof McKone for the review and we will iterate the manuscript taking into account the suggestion to compare the different reference equations (Knudson vs GLI) using Bland-Altman analysis.
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We concur the GLI has been recently accepted as the standard for most CF registries.
We concur that regression analyses is preferable to determine FEV1 decline. As recommended by Prof Burgel, we will replace the term "FEV1 decline" with "year-to-year FEV1 variation" in the revised manuscript.
We concur that the method used to adjust year-to-year FEV1 variation for baseline FEV1 is crude. The displayed data from the ESCF paper is only presented according to the four FEV1 categories, hence our choice of adjustment method. Given the limited number of subjects within the Sheffield dataset, we felt is it is more appropriate to use reference values for suitably large datasets instead of simply calculating the predicted %FEV1 change using the Sheffield dataset. There are more recent reference values for FEV1 from the ECFSPR (Boëlle et al, 2012) and Canadian registry (Kim et al, 2018) ; however those papers do not provide reference values for year-to-year FEV1 variation.
Our statistical method account for repeated FEV1 measures since: 1. by using best FEV1, there is only x1 FEV1 reading per person per year 2. only x1 FEV1 reading per person was used to calculate the year-to-year FEV1 variation As mentioned in the discussion section, we concur that a single-centre study may not be generalisable. However, inaccurate data recording within routine datasets (e.g. CF registries) is unlikely to be an isolated problem. For example, the letter by Hartley et al (2016) in JCF revealed that 6% of the adults with CF at the Manchester Adult CF Centre had incorrect genotype data recorded in the UK CF registry.
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